LONSURF (trifluridine/tipiracil), pyrimidine analogue
ONCOLOGY - New medicinal product
Opinions on drugs - Posted on Aug 28 2017
Reason for request
No clinical added value in the treatment of metastatic colorectal cancer
LONSURF, administered orally, has a marketing authorisation in the treatment of metastatic colorectal cancer (mCRC) patients previously treated with available treatments including chemotherapies based on fluoropyrimidine, oxaliplatin and irinotecan, anti-VEGF agents and anti-EGFR agents, or in cases of noneligibility for these treatments.
- Its effect is modest on overall survival and progression-free survival at the price of haematological toxicity mainly.
- There are no data on quality of life based on a validated scale.
Clinical Added Value
|no clinical added value||
Évaluation des médicaments